Combination of Imvotamab and Loncastuximab Tesirine Shows Enhanced Anti‐Tumor Activity in a Preclinical Model of Non‐Hodgkin’s LymphomaKathryn Logronio, M. F. Kotturi, Miho Oyasu et al.|Hematological Oncology|2023Cited by 2